Moleculin Biotech (MBRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- CNS Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 92/100 (CRITICAL), 3.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.87% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Moleculin Announces Reverse Stock Split
- Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
- Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
- Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
- Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
- Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
- Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
- Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). — J Clin Oncol 2026 Aug PMID 42272166
- A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. — Oncologist 2026 Jun 6 PMID 42268676
- A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. — Cancer 2026 Mar 15 PMID 41817106
- First-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients. — JCI Insight 2026 Feb 9 PMID 41379553
- Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. — Blood Adv 2026 Mar 10 PMID 41351513
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Moleculin Biotech.
Full MBRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.